Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist

  • ACS Med Chem Lett. 2012 Oct 1;3(12):985-90. doi: 10.1021/ml3002083.
Mary Liang  1 ,  Tyler B Tarr  1 ,  Karla Bravo-Altamirano  1 ,  Guillermo Valdomir  1 ,  Gabriel Rensch  1 ,  Lauren Swanson  1 ,  Nicholas R DeStefino  1 ,  Cara M Mazzarisi  1 ,  Rachel A Olszewski  1 ,  Gabriela Mustata Wilson  1 ,  Stephen D Meriney  1 ,  Peter Wipf  1
Affiliations
  • 1. Department of Chemistry, Department of Neuroscience and Center for Neuroscience, and Department of Computational and Systems Biology, University of Pittsburgh , Pittsburgh, Pennsylvania 15260, United States.
PMID: 24936234 DOI: 10.1021/ml3002083
Abstract

The acute effect of the potent cyclin-dependent kinase (CDK) inhibitor (R)-roscovitine on CA(2+) channels inspired the development of structural analogues as a potential treatment for motor nerve terminal dysfunction. On the basis of a versatile chlorinated purine scaffold, we have synthesized CA. 20 derivatives and characterized their N-type CA(2+) channel agonist action. Agents that showed strong agonist effects were also characterized in a kinase panel for their off-target effects. Among several novel compounds with diminished CDK activity, we identified a new lead structure with a 4-fold improved N-type CA(2+) channel agonist effect and a 22-fold decreased CDK2 activity as compared to (R)-roscovitine. This compound was selective for agonist activity on N- and P/Q-type over L-type calcium channels.

Keywords
LEMS; Lambert−Eaton myasthenic syndrome; N/P/Q-type calcium channels; cdk2; neurological autoimmune disorder; roscovitine; selective agonist.
Products